Arrowhead Pharmaceuticals (ARWR) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
13 Nov, 2026Executive summary
FY26 marked a shift toward commercialization, led by REDEMPLO’s FCS launch and preparation for a potential SHTG launch in Q2 2027, subject to FDA approval.
Pipeline advances included pivotal SHTG results, dual-target RNAi data from ARO-DIMER-PA, and initial evidence of subcutaneous RNAi delivery to the CNS with ARO-MAPT.
Management’s priorities include growing REDEMPLO’s reach, expanding RNAi across tissues and targets, and building infrastructure to support multiple products.
Financial highlights
FY26 revenue was $450.817M versus $829.448M in FY25; FY26 included $317M from Sarepta, $89M from Novartis, $25M from Madrigal, $13.3M from Sanofi, and ~$6.6M of REDEMPLO net product revenue.
FY26 net loss was $724.206M, or $5.11 per share, versus $1.631M, or $0.01 per share, in FY25; excluding the $215M one-time PRV expense, FY26 net loss would have been ~$509M.
FY26 operating expenses were $1,157.988M versus $731M in FY25; excluding the PRV expense, expenses were ~$943M, up $212M year over year.
FY26 R&D was $739.144M versus $607.159M, and SG&A was $202.045M versus $123.943M; higher SG&A primarily reflected REDEMPLO commercialization investment.
Outlook and guidance
Potential U.S. SHTG launch targeted for Q2 2027, subject to FDA review and approval; the plozasiran sNDA was submitted November 2 and entered the STAR review pilot.
No SHTG revenue guidance yet; visibility depends on the FDA label, PDUFA timing, and payer experience. Early launch indicators include new-to-brand prescriptions, distinct prescribers, and covered lives.
Management sees potential for REDEMPLO to generate $3B–$4B in annual U.S. SHTG sales over time; the initial high-risk target population is nearly 1M U.S. patients.
Planned milestones include additional obesity data by year-end 2026, ARO-DIMER-PA data in H1 2027, YOSEMITE data in H2 2027, and initial ARO-MAPT patient data in H2 2027.
YOSEMITE zodasiran Phase 3 is expected to complete in mid-2027; regulatory filings in multiple geographies are planned subject to successful results.
Latest events from Arrowhead Pharmaceuticals
- REDEMPLO sHTG review and multiple 2027 pipeline milestones anchor the outlook.ARWR
Jefferies Global Healthcare Conference - ARO-MAPT cut CSF tau by up to 73% at Day 105, supporting quarterly-or-less-frequent dosing.ARWR
Study update - Breakthrough dual gene knockdown, robust triglyceride therapy, and pipeline innovation drive growth.ARWR
Morgan Stanley 24th Annual Global Healthcare Conference - Pivotal RNAi trial results and new launches set the stage for major growth across multiple indications.ARWR
H.C. Wainwright 28th Annual Global Investment Conference - Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry.ARWR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Plozasiran delivers robust, sustained efficacy and safety for high-risk SHTG patients.ARWR
KOL event - SHASTA-3/4 trials drove strong efficacy, revenue growth, and global REDEMPLO expansion.ARWR
Q3 2026 - Plozasiran nears launch after robust phase III data, with lung program readouts expected soon.ARWR
Chardan's 8th Annual Genetic Medicines Conference - Q2 FY2025 saw $542.7M revenue, $370.4M net income, and funding secured into 2028.ARWR
Q2 2025